Glaucoma: The Fight to Prevent Blindness - Medical Frontiers

Key Concepts

• Glaucoma: A progressive optic nerve damage, often linked to increased intraocular pressure, leading to irreversible vision loss.
• Optic Nerve: The nerve transmitting visual information from the retina to the brain.
• Aqueous Humor: The fluid within the eye that maintains pressure and provides nutrients.
• Intraocular Pressure (IOP): The pressure inside the eye, measured in millimeters of mercury (mmHg). Normal range is 10-21 mmHg.
• Normal Tension Glaucoma: Glaucoma occurring with IOP within the normal range, potentially due to optic nerve vulnerability.
• BDNF (Brain-Derived Neurotrophic Factor): A protein crucial for nerve cell survival and function, with reduced levels observed in glaucoma patients.
• Gene Therapy: A technique involving altering genes to treat or prevent disease, explored for optic nerve regeneration.
• Micro Shunt Surgery: A newer surgical technique using a tiny tube to improve aqueous humor drainage.

Glaucoma: A Silent Threat to Vision

Glaucoma, often referred to as the “silent thief of sight,” is a disease that progressively damages the optic nerve, potentially leading to irreversible blindness. Approximately 70 million people worldwide currently have glaucoma, with projections exceeding 100 million by 2040, according to the American Academy of Ophthalmology. The eye functions by refracting light through the cornea and lens onto the retina, transmitting the image via the optic nerve to the brain for interpretation. Damage to the optic nerve disrupts this process.

Stages of Glaucoma & Detection Challenges

Glaucoma progresses through three stages:

• Early Stage: Typically asymptomatic, with initial loss of peripheral vision often unnoticed due to the remaining intact vision.
• Moderate Stage: Visual field defects enlarge, potentially causing blurry vision or worsening eyesight. Compensation by the unaffected eye can mask symptoms. A Japanese survey revealed that 1 in 20 people in their 40s had glaucoma, yet 90% were unaware and untreated.
• Advanced Stage: Significant central vision loss occurs, leading to severe impairment and potential blindness without intervention.

The insidious nature of glaucoma makes early detection crucial. Professor Shoji Noyuki of the Japan Glaucoma Society emphasizes the importance of regular check-ups, even in the absence of symptoms.

Understanding the Mechanisms of Glaucoma

The primary cause of glaucoma is often linked to increased intraocular pressure (IOP). The eye maintains its shape and function due to the balance between the production and drainage of aqueous humor, a clear fluid between the cornea and lens. Disruption of this balance leads to elevated IOP, damaging the optic nerve. The international standard for normal IOP is 10-21 mmHg, with pressures exceeding this level posing a risk.

However, a significant proportion of glaucoma cases, particularly in Japan (over 70% according to the Japan Glaucoma Society), are classified as normal tension glaucoma. This suggests that some individuals have optic nerves that are more susceptible to damage even at normal IOP levels. The exact cause of this vulnerability remains unknown. Family history is a risk factor, as highlighted by Professor Noyuki, prompting individuals with affected relatives to be particularly vigilant.

Current Treatment Strategies

Currently, medical interventions for glaucoma focus on managing the condition and preventing further progression, as restoring lost vision remains a challenge.

• Eye Drops: The first line of treatment, targeting aqueous humor by reducing its production or enhancing drainage. Studies show that a 1 mmHg reduction in IOP correlates with a 10% decrease in glaucoma risk. A Japanese clinical trial demonstrated that eye drops reduced IOP by 6.6 mmHg within one month, with sustained effects.
• Surgery: Employed when eye drops are insufficient. Traditional surgical methods aim to improve aqueous humor drainage through the trabecular meshwork (the opening between the cornea and iris). However, these can be prone to complications like re-clogging or excessive fluid drainage.
• Micro Shunt Surgery (2023 approval in Japan): A newer technique utilizing a tiny (8.5mm long, 0.07mm diameter) micro shunt inserted through a small incision in the sclera. This creates a new drainage pathway for aqueous humor. Clinical trials indicate it’s quicker, causes less bleeding, and reduces the risk of re-closure compared to traditional excision procedures, although it may be slightly less effective at lowering IOP initially. A study of 400 patients in the US and Europe showed sustained IOP reduction to a normal range (13 mmHg) two years post-surgery, starting from an initial pressure of 21 mmHg.

Emerging Research: Optic Nerve Regeneration

Despite the limitations of current treatments, promising research is underway to explore optic nerve regeneration. A Japanese research team led by Harada Takayuki at the Tokyo Metropolitan Institute of Medical Science is investigating the potential of gene therapy to increase levels of Brain-Derived Neurotrophic Factor (BDNF) in the eye.

• BDNF’s Role: BDNF, a protein vital for nerve cell survival and function, is found to be deficient in glaucoma patients. Harada’s research focuses on strengthening the optic nerve by boosting BDNF levels.
• Gene Therapy Approach: The team utilizes a modified, harmless virus to deliver a protein called track B into optic nerve cells. Track B facilitates the delivery of BDNF-related information, protecting and potentially regenerating damaged nerve cells.
• Experimental Results: In mice with glaucoma, the track B modified virus reduced nerve cell loss and promoted optic nerve regeneration, as demonstrated by imaging showing increased nerve fiber growth. These findings have garnered attention from researchers like Jeffrey L. Goldberg at Stanford University, who praised the approach as “creative” and potentially applicable to other neurodegenerative diseases. Further testing is required to ensure safety and efficacy for human use.

Early Detection & Self-Checks

Professor Noyuki stresses the importance of early detection, even in the absence of symptoms. He suggests a simple self-check: cover one eye, focus on a point, and repeat with the other eye, noting any differences in brightness or the presence of dark areas. He also emphasizes the correct technique for administering eye drops – aiming for the eyebrow and gently pressing the inner corner of the eye for a minute to maximize absorption.

Conclusion

Glaucoma remains a significant threat to vision worldwide. While current treatments can manage the condition and prevent further damage, they cannot restore lost vision. Ongoing research, particularly in the field of gene therapy and BDNF enhancement, offers hope for future treatments that may protect and even regenerate the optic nerve. Early detection through regular eye exams and self-checks is paramount in preserving vision and mitigating the impact of this “silent thief.”